Synthesis and biological evaluation of 2-aminothiazole-thiazolidinone conjugates as potential antitubercular agents. 2018

Mahmoud F Abo-Ashour, and Wagdy M Eldehna, and Riham F George, and Marwa M Abdel-Aziz, and Mahmoud M Elaasser, and Sahar M Abou-Seri, and Nagwa M Abdel Gawad
Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Egyptian Russian University, Badr City, Cairo 11829, Egypt.

Mycobacterium tuberculosis, which causes tuberculosis, continues to infect millions of the global population, resulting in 1.8 million deaths worldwide in 2015. Hybrids of 2-amino-4-methylthiazole bearing 5-acetyl/5-ethyl carboxylate functionality with 5-arylidene thiazolidinone moiety (6a-k and 9a-d) were synthesized and screened for antitubercular and antimicrobial activities. 5-ethyl carboxylate derivative 6k revealed half antitubercular activity (minimal inhibitory concentration = 1.56 μg/ml) than the acetyl analog 6c (minimal inhibitory concentration = 0.78 μg/ml), however, it exhibited more potent broad spectrum antibacterial and antifungal activities in addition to its excellent safety profile with high selectivity toward M. tuberculosis over normal human lung cells. Collectively, these data suggested that compound 6k can be considered as an ideal lead compound for further optimization.

UI MeSH Term Description Entries
D008826 Microbial Sensitivity Tests Any tests that demonstrate the relative efficacy of different chemotherapeutic agents against specific microorganisms (i.e., bacteria, fungi, viruses). Bacterial Sensitivity Tests,Drug Sensitivity Assay, Microbial,Minimum Inhibitory Concentration,Antibacterial Susceptibility Breakpoint Determination,Antibiogram,Antimicrobial Susceptibility Breakpoint Determination,Bacterial Sensitivity Test,Breakpoint Determination, Antibacterial Susceptibility,Breakpoint Determination, Antimicrobial Susceptibility,Fungal Drug Sensitivity Tests,Fungus Drug Sensitivity Tests,Sensitivity Test, Bacterial,Sensitivity Tests, Bacterial,Test, Bacterial Sensitivity,Tests, Bacterial Sensitivity,Viral Drug Sensitivity Tests,Virus Drug Sensitivity Tests,Antibiograms,Concentration, Minimum Inhibitory,Concentrations, Minimum Inhibitory,Inhibitory Concentration, Minimum,Inhibitory Concentrations, Minimum,Microbial Sensitivity Test,Minimum Inhibitory Concentrations,Sensitivity Test, Microbial,Sensitivity Tests, Microbial,Test, Microbial Sensitivity,Tests, Microbial Sensitivity
D009169 Mycobacterium tuberculosis A species of gram-positive, aerobic bacteria that produces TUBERCULOSIS in humans, other primates, CATTLE; DOGS; and some other animals which have contact with humans. Growth tends to be in serpentine, cordlike masses in which the bacilli show a parallel orientation. Mycobacterium tuberculosis H37Rv
D002460 Cell Line Established cell cultures that have the potential to propagate indefinitely. Cell Lines,Line, Cell,Lines, Cell
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000995 Antitubercular Agents Drugs used in the treatment of tuberculosis. They are divided into two main classes: "first-line" agents, those with the greatest efficacy and acceptable degrees of toxicity used successfully in the great majority of cases; and "second-line" drugs used in drug-resistant cases or those in which some other patient-related condition has compromised the effectiveness of primary therapy. Anti-Tuberculosis Agent,Anti-Tuberculosis Agents,Anti-Tuberculosis Drug,Anti-Tuberculosis Drugs,Antitubercular Agent,Antitubercular Drug,Tuberculostatic Agent,Tuberculostatic Agents,Antitubercular Drugs,Agent, Anti-Tuberculosis,Agent, Antitubercular,Agent, Tuberculostatic,Anti Tuberculosis Agent,Anti Tuberculosis Agents,Anti Tuberculosis Drug,Anti Tuberculosis Drugs,Drug, Anti-Tuberculosis,Drug, Antitubercular
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D013844 Thiazoles Heterocyclic compounds where the ring system is composed of three CARBON atoms, a SULFUR and NITROGEN atoms. Thiazole
D014376 Tuberculosis Any of the infectious diseases of man and other animals caused by species of MYCOBACTERIUM TUBERCULOSIS. Koch's Disease,Kochs Disease,Mycobacterium tuberculosis Infection,Infection, Mycobacterium tuberculosis,Infections, Mycobacterium tuberculosis,Koch Disease,Mycobacterium tuberculosis Infections,Tuberculoses
D015195 Drug Design The molecular designing of drugs for specific purposes (such as DNA-binding, enzyme inhibition, anti-cancer efficacy, etc.) based on knowledge of molecular properties such as activity of functional groups, molecular geometry, and electronic structure, and also on information cataloged on analogous molecules. Drug design is generally computer-assisted molecular modeling and does not include PHARMACOKINETICS, dosage analysis, or drug administration analysis. Computer-Aided Drug Design,Computerized Drug Design,Drug Modeling,Pharmaceutical Design,Computer Aided Drug Design,Computer-Aided Drug Designs,Computerized Drug Designs,Design, Pharmaceutical,Drug Design, Computer-Aided,Drug Design, Computerized,Drug Designs,Drug Modelings,Pharmaceutical Designs
D053778 Thiazolidines Reduced (protonated) form of THIAZOLES. They can be oxidized to THIAZOLIDINEDIONES. Thiazolidine

Related Publications

Mahmoud F Abo-Ashour, and Wagdy M Eldehna, and Riham F George, and Marwa M Abdel-Aziz, and Mahmoud M Elaasser, and Sahar M Abou-Seri, and Nagwa M Abdel Gawad
April 2014, Bioorganic & medicinal chemistry letters,
Mahmoud F Abo-Ashour, and Wagdy M Eldehna, and Riham F George, and Marwa M Abdel-Aziz, and Mahmoud M Elaasser, and Sahar M Abou-Seri, and Nagwa M Abdel Gawad
October 2020, Archiv der Pharmazie,
Mahmoud F Abo-Ashour, and Wagdy M Eldehna, and Riham F George, and Marwa M Abdel-Aziz, and Mahmoud M Elaasser, and Sahar M Abou-Seri, and Nagwa M Abdel Gawad
June 2013, European journal of medicinal chemistry,
Mahmoud F Abo-Ashour, and Wagdy M Eldehna, and Riham F George, and Marwa M Abdel-Aziz, and Mahmoud M Elaasser, and Sahar M Abou-Seri, and Nagwa M Abdel Gawad
January 2014, Bioorganic & medicinal chemistry letters,
Mahmoud F Abo-Ashour, and Wagdy M Eldehna, and Riham F George, and Marwa M Abdel-Aziz, and Mahmoud M Elaasser, and Sahar M Abou-Seri, and Nagwa M Abdel Gawad
May 2018, Future medicinal chemistry,
Mahmoud F Abo-Ashour, and Wagdy M Eldehna, and Riham F George, and Marwa M Abdel-Aziz, and Mahmoud M Elaasser, and Sahar M Abou-Seri, and Nagwa M Abdel Gawad
November 2011, Chemical biology & drug design,
Mahmoud F Abo-Ashour, and Wagdy M Eldehna, and Riham F George, and Marwa M Abdel-Aziz, and Mahmoud M Elaasser, and Sahar M Abou-Seri, and Nagwa M Abdel Gawad
August 2023, Archiv der Pharmazie,
Mahmoud F Abo-Ashour, and Wagdy M Eldehna, and Riham F George, and Marwa M Abdel-Aziz, and Mahmoud M Elaasser, and Sahar M Abou-Seri, and Nagwa M Abdel Gawad
October 2012, European journal of medicinal chemistry,
Mahmoud F Abo-Ashour, and Wagdy M Eldehna, and Riham F George, and Marwa M Abdel-Aziz, and Mahmoud M Elaasser, and Sahar M Abou-Seri, and Nagwa M Abdel Gawad
January 2016, Molecules (Basel, Switzerland),
Mahmoud F Abo-Ashour, and Wagdy M Eldehna, and Riham F George, and Marwa M Abdel-Aziz, and Mahmoud M Elaasser, and Sahar M Abou-Seri, and Nagwa M Abdel Gawad
January 2021, Drug design, development and therapy,
Copied contents to your clipboard!